Related Experiment Videos
Beta 2-adrenoceptor antagonism in anxiety
S J Cooper1, C B Kelly, S McGilloway
1Department of Mental Health, Queen's University, Belfast, U.K.
Summary
Selective beta 2-adrenoceptor antagonism with ICI 118,551 did not effectively manage acute anxiety symptoms. Beta 2-blockers appear ineffective for anxiety neurosis, suggesting beta 1-antagonism may be more crucial.
Area of Science:
- Pharmacology
- Clinical Psychology
- Neuroscience
Background:
- The precise role of beta 1- and beta 2-adrenoceptor antagonism in treating anxiety symptoms remains unclear.
- Understanding these mechanisms is vital for developing targeted anxiety management strategies.
Purpose of the Study:
- To investigate the efficacy of ICI 118,551, a selective beta 2-adrenoceptor antagonist, in patients with acute anxiety symptoms.
- To compare the effects of beta 2-antagonism with diazepam and placebo in managing anxiety disorders.
Main Methods:
- A double-blind, randomized trial involving 51 patients diagnosed with anxiety disorder.
- Participants received a 4-week treatment course of placebo, diazepam (2 mg thrice daily), or ICI 118,551 (50 mg thrice daily) after an initial placebo week.
- Anxiety symptoms were assessed using the Hamilton Anxiety Scale.
Main Results:
- All treatment groups showed improvement in Hamilton Anxiety Scale scores.
- No statistically significant differences in anxiety symptom improvement were observed between ICI 118,551, diazepam, and placebo treatments.
- Beta 2-adrenoceptor antagonism demonstrated no significant benefit in acute anxiety neurosis.
Conclusions:
- Selective beta 2-adrenoceptor antagonism is not an effective treatment for acute anxiety neurosis.
- These findings suggest that beta 1-adrenoceptor antagonism might play a more significant role in anxiety symptom management.
- Further research into beta 1-selective antagonists for anxiety is warranted.